xmlns:atom="http://www.w3.org/2005/Atom" xmlns:atom="http://www.w3.org/2005/Atom"
Valid from 01/04/2010
Valid from 21/05/2010
6E+WIn this Part of this Schedule “the NHS (Wales) Act” means the National Health Service (Wales) Act 2006 (c. 42).
7E+WIn section 174 of the NHS (Wales) Act (public funding of Local Health Boards) omit “and pharmaceutical” in—
(a)subsection (1)(a),
(b)subsection (2)(a) and (b), and
(c)subsection (12).
8E+WIn section 175 of the NHS (Wales) Act (financial duties of Local Health Boards), in subsection (1) omit “and pharmaceutical”.
9E+WIn section 176 of the NHS (Wales) Act (resource limits for Local Health Boards) omit “and pharmaceutical” in—
(a)subsection (2), and
(b)subsection (3)(b).
10(1)Schedule 8 to the NHS (Wales) Act (further provision about expenditure of Local Health Boards) is amended as follows.E+W
(2)In paragraph 1(1)—
(a)omit “and pharmaceutical”, and
(b)in paragraph (a) for the words from “services under” to “pharmaceutical services)” substitute “ general ophthalmic services ”.
(3)In paragraph 1(2)—
(a)in paragraph (a) for “services as mentioned in sub-paragraph (1)(a)” substitute “ general ophthalmic services ”, and
(b)omit paragraphs (b) and (c).
(4)Accordingly, in the heading immediately preceding paragraph 1, omit “and pharmaceutical”.
(5)For paragraph 2 substitute—
“2In section 174 “main expenditure”, in relation to a Local Health Board and the year in question, means—
(a)expenditure of the Local Health Board attributable to the reimbursement in that year of expenses of persons providing general ophthalmic services which are designated expenses incurred in connection with the provision of those services (or in giving instruction in matters relating to those services), and
(b)any other expenditure of the Local Health Board attributable to the performance of its functions in that year (other than general ophthalmic services expenditure).”
(6)After paragraph 3 insert—
“3A(1)The Welsh Ministers may designate any element of the remuneration paid by Local Health Boards to persons providing pharmaceutical services or local pharmaceutical services which is not remuneration referable to the cost of drugs.
(2)If an element is so designated, the Welsh Ministers must for each financial year apportion among all Local Health Boards, in such manner as the Welsh Ministers consider appropriate, the total of the remuneration referable to that element which is paid by each Local Health Board in that year.
(3)A Local Health Board is accountable in any year for remuneration referable to that element to the extent (and only to the extent) that such remuneration is apportioned to it under sub-paragraph (2).
(4)Where in any financial year any remuneration referable to that element for which a Local Health Board is accountable is paid by another Local Health Board, the remuneration must be treated (for the purposes of sections 174 and 175) as having been paid by the first Local Health Board in the performance of its functions.
(5)The Welsh Ministers may, in particular, exercise their discretion under sub-paragraph (2)—
(a)so that any apportionment relating to services associated with the provision of drugs reflects, in the case of each Local Health Board, the financial consequences of orders for the provision of drugs, being orders which in the opinion of the Welsh Ministers are attributable to the Board in question,
(b)by reference to averaged or estimated amounts.
(6)The Welsh Ministers may make provision for any remuneration referable to an element designated under sub-paragraph (1) which is paid by a Local Health Board other than the Board which is accountable for the payment to be reimbursed in such manner as the Welsh Ministers may determine.”
(7)In paragraph 4(1)—
(a)at the end of the definition of “designated” insert “ and “designate” must be read accordingly ”,
(b)omit the definition of “pharmaceutical services”, and
(c)in the definition of “remuneration referable to the cost of drugs”, omit the words “except in paragraph 1(2)(b) and”.
(8)After paragraph 4(3) insert—
“(4)If the Welsh Ministers do not treat such remuneration, so far as it is so met by an NHS trust, as remuneration referable to the cost of drugs, they may treat it as remuneration falling within paragraph 3A(1).”